News - Immunic Therapeutics

Press Releases & Events

Latest News

Latest news

Posted by Steffi I.

May 17, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Posted by Steffi I.

May 11, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Posted by Steffi I.

May 9, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update

Posted by Steffi I.

May 6, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Posted by Steffi I.

May 4, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

Posted by Steffi I.

April 27, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Posted by Steffi I.

April 26, 2023

Immunic to Participate in Investor and Scientific Conferences in May

Posted by Steffi I.

April 5, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

2023

Posted by Steffi I.

May 17, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Posted by Steffi I.

May 11, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Posted by Steffi I.

May 9, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update

Posted by Steffi I.

May 6, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

Posted by Steffi I.

May 4, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

Posted by Steffi I.

April 27, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Posted by Steffi I.

April 26, 2023

Immunic to Participate in Investor and Scientific Conferences in May

Posted by Steffi I.

April 5, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Posted by Steffi I.

March 2, 2023

Immunic to Participate in Investor and Scientific Conferences in March

Posted by Steffi I.

February 23, 2023

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

Posted by Steffi I.

February 22, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Posted by Steffi I.

February 16, 2023

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

Posted by Steffi I.

February 9, 2023

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Posted by Steffi I.

January 25, 2023

Immunic to Participate in Scientific and Investor Conferences in February

2022

Posted by Steffi I.

November 17, 2022

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential

Posted by Steffi I.

November 10, 2022

Immunic to Participate in Investor and Scientific Conferences in November and December

Posted by Steffi I.

November 3, 2022

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Posted by Steffi I.

October 27, 2022

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

Posted by Steffi I.

October 20, 2022

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Posted by Jessica

October 10, 2022

Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing

Posted by Steffi I.

October 4, 2022

Immunic to Participate in Scientific and Industry Conferences in October

Posted by Steffi I.

September 20, 2022

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Posted by Steffi I.

September 1, 2022

Immunic, Inc. to Participate in Investor Conferences in September

Posted by Steffi I.

August 16, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Posted by Steffi I.

August 4, 2022

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Posted by Steffi I.

August 2, 2022

Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Posted by Steffi I.

July 28, 2022

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

Posted by Steffi I.

July 6, 2022

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

Posted by Steffi I.

June 28, 2022

Immunic to Participate in Industry and Scientific Conferences in July

Posted by Steffi I.

June 15, 2022

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Posted by Steffi I.

June 8, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June

Posted by Steffi I.

June 2, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Posted by Steffi I.

May 10, 2022

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

Posted by Steffi I.

May 5, 2022

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Posted by Steffi I.

May 3, 2022

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

Posted by Steffi I.

April 25, 2022

Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences

Posted by Steffi I.

March 16, 2022

Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

Posted by Steffi I.

March 8, 2022

Immunic, Inc. to Participate in Investor and Scientific Conferences in March

Posted by Steffi I.

February 24, 2022

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

Posted by Steffi I.

February 18, 2022

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn’s and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Posted by Steffi I.

February 17, 2022

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

Posted by Steffi I.

February 8, 2022

Immunic, Inc. to Participate in Investor and Scientific Conferences in February

Posted by Steffi I.

February 2, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

2021

Posted by Steffi I.

December 14, 2021

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

Posted by Steffi I.

December 9, 2021

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

Posted by Steffi I.

November 23, 2021

Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference

Posted by Steffi I.

November 18, 2021

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

Posted by Steffi I.

November 4, 2021

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

Posted by Steffi I.

November 1, 2021

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2021 and Provide Corporate Update

Posted by Steffi I.

October 28, 2021

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

Posted by Steffi I.

October 27, 2021

Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935

Posted by Steffi I.

October 14, 2021

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Posted by Steffi I.

September 30, 2021

Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

Posted by Steffi I.

September 28, 2021

Immunic, Inc. to Participate in Scientific and Investor Conferences in October

Posted by Steffi I.

September 22, 2021

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Posted by Steffi I.

September 8, 2021

Immunic, Inc. to Participate in Investor and Scientific Conferences in September

Posted by Steffi I.

August 6, 2021

Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

Posted by Jessica

August 3, 2021

Immunic, Inc. to Participate in Investor Conferences in August

Posted by Jessica

July 19, 2021

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Posted by Jessica

July 15, 2021

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

Posted by Jessica

July 14, 2021

Immunic, Inc. Announces Proposed Public Offering of Common Stock

Posted by Jessica

July 12, 2021

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

Posted by Jessica

July 1, 2021

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Posted by Jessica

June 28, 2021

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July

Posted by Jessica

June 10, 2021

Immunic, Inc. to Participate in Industry and Investor Conferences in June

Posted by Jessica

June 1, 2021

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

Posted by Jessica

May 17, 2021

BEAT-COV Endorses Initiative of the German Government for EUR 300 Million Funding Program for Late-Stage COVID-19 Therapies (in German Only)

Posted by Jessica

May 6, 2021

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

Posted by Jessica

April 15, 2021

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838’s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

Posted by Jessica

April 13, 2021

Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

Posted by Jessica

March 31, 2021

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

Posted by Jessica

March 2, 2021

Immunic, Inc. to Participate in Industry and Investor Conferences in March

Posted by Jessica

February 26, 2021

Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

Posted by Jessica

February 18, 2021

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Posted by Jessica

February 17, 2021

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Posted by Jessica

February 11, 2021

Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25

Posted by Jessica

January 5, 2021

Immunic, Inc. to Participate in Investor Conferences in January

2020

Posted by Jessica

December 14, 2020

Immunic, Inc. Added to NASDAQ Biotechnology Index

Posted by Jessica

December 2, 2020

BEAT-COV Initiative Requests Support for the Development and Production of New, Innovative COVID-19 Therapies (in German Only)

Posted by Jessica

November 24, 2020

Immunic, Inc. to Participate in Investor Conferences in December

Posted by Jessica

November 17, 2020

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

Posted by Jessica

November 10, 2020

Immunic, Inc. to Participate in Investor and Scientific Conferences in November

Posted by Jessica

November 5, 2020

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Posted by Jessica

November 2, 2020

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Posted by Jessica

October 20, 2020

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

Posted by Jessica

September 29, 2020

Immunic, Inc. to Participate in Scientific Conferences in October

Posted by Jessica

September 28, 2020

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

Posted by Jessica

September 11, 2020

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

Posted by Jessica

September 8, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in September

Posted by Jessica

August 20, 2020

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Posted by Jessica

August 10, 2020

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Posted by Jessica

August 5, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Posted by Jessica

August 3, 2020

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock

Posted by Jessica

August 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Posted by Jessica

July 30, 2020

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Posted by Jessica

July 29, 2020

Immunic, Inc. to Participate in Investor Conferences in August

Posted by Jessica

July 27, 2020

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

Posted by Jessica

June 22, 2020

Immunic, Inc. to Join Russell 3000® Index

Posted by Jessica

June 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Posted by Jessica

June 10, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

Posted by Jessica

June 10, 2020

Immunic, Inc. Announces Proposed Public Offering of Common Stock

Posted by Jessica

June 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Posted by Jessica

May 29, 2020

Immunic, Inc. to Participate in Investor and Industry Conferences in June

Posted by Jessica

May 19, 2020

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

Posted by Jessica

May 13, 2020

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

Posted by Jessica

May 8, 2020

Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity

Posted by Jessica

April 23, 2020

Immunic, Inc. Announces Pricing of $15 Million Financing

Posted by Jessica

April 21, 2020

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

Posted by Jessica

April 17, 2020

Immunic, Inc. Announces Changes to Executive Team

Posted by Jessica

March 15, 2020

Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

Posted by Jessica

February 11, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in February

Posted by Jessica

January 8, 2020

Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.

2019

Posted by Jessica

December 4, 2019

Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn’s and Colitis Foundation’s IBD Innovate Conference

Posted by Jessica

November 25, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in December

Posted by Jessica

November 19, 2019

Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips

Posted by Jessica

November 7, 2019

Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity

Posted by Jessica

November 5, 2019

Immunic, Inc. to Participate in Industry and Investor Conferences in November

Posted by Jessica

October 15, 2019

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

Posted by Jessica

October 10, 2019

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Posted by Jessica

September 30, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in October

Posted by Jessica

September 18, 2019

Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

Posted by Jessica

September 11, 2019

Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019

Posted by Jessica

September 5, 2019

Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

Posted by Jessica

September 3, 2019

Immunic, Inc. to Participate in Scientific and Investor Conferences in September

Posted by Jessica

August 12, 2019

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis

Posted by Jessica

August 8, 2019

Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity

Posted by Jessica

August 1, 2019

Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project

Posted by Jessica

July 30, 2019

Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8

Posted by Jessica

July 16, 2019

Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer

Posted by Jessica

June 24, 2019

Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston

Posted by Jessica

June 21, 2019

Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update

Posted by Jessica

June 4, 2019

Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway

Posted by Jessica

May 30, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in June

Posted by Jessica

May 9, 2019

Immunic, Inc. to Participate in Upcoming May Conferences

Posted by Jessica

April 29, 2019

Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer

Posted by Jessica

April 12, 2019

Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

Posted by Jessica

April 2, 2019

Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10

Posted by Jessica

February 28, 2019

Immunic Therapeutics to Participate in Investor and Medical Conferences in March

Posted by Jessica

February 26, 2019

Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis

Posted by Jessica

February 6, 2019

Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11

Posted by Jessica

January 7, 2019

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

2018

Posted by Jessica

November 5, 2018

Immunic enters into a global option and license agreement with Daiichi Sankyo

Posted by Jessica

April 26, 2018

Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis

Posted by Jessica

January 11, 2018

FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis

2017

Posted by Jessica

January 8, 2021

Development of Innovative COVID-19 Therapies Needs Additional Public Funding to Help Patients in the Short-Term (in German Only)

Posted by Jessica

December 12, 2017

Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838

Posted by Jessica

September 5, 2017

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Posted by Jessica

February 1, 2017

Immunic Adds EUR 4 Million in Funding to Further Boost Development

Posted by Jessica

January 9, 2017

Immunic strengthens Management Team and Supervisory Board

2016

Posted by Jessica

September 28, 2016

Immunic acquires 4SC’s immunology portfolio

Posted by Jessica

September 27, 2016

Immunic successfully closes 17.5 million Euro Series A financing round

Media and Investor Inquiries

Questions?
Get in touch.

Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09

Send an Email